### **Resonance Health News**



June 2016

Welcome to our second newsletter of 2016, bringing you a summary of our global promotional activities, potential new indications for FerriScan<sup>®</sup> and HepaFat-Scan<sup>®</sup>, plus other exciting developments

## **Customer in Focus: Barts Heart Centre**

Resonance Health is proud to have been collaborating with Barts Health in London since 2009. The <u>Barts Heart Centre</u> is among the first sites in the UK to now offer HepaFat-Scan to patients in conjunction with FerriScan. Barts Heart Centre is a spectacular new facility that amalgamates the services of several of London's specialist cardiac and chest units into a single state-of-the-art resource. During his recent conference tour of Europe, Resonance Health's Chief Scientific Officer, Professor St Pierre, took the opportunity to present Professor James Moon, Consultant Cardiologist and Director of Cardiac Imaging Services at Barts Heart Centre, with a Certificate of Verification for both HepaFat-Scan and FerriScan. Professor Moon has been a long-standing supporter and research partner of Resonance Health.



*L* to *R*: Prof. James Moon (Barts Heart Centre) receiving a Certificate of Verification from Prof. Tim St Pierre (Resonance Health)

The Barts Heart Centre recently re-scanned the 120 participants for a follow-up HepaFat-Scan for the London Marathon Study, held in May. HepaFat-Scan is being used alongside cardiac MRI measurements taken before the Marathon training and after the event to assess the impact of intense exercise on both liver fat fraction and cardiac function. HepaFat-Scan data from the study is currently being analysed and we look forward to continued participation with the event.

## **Conference Round Up**



The April to June quarter was hugely busy, with many conference presentations and disease-focussed events held and attended in Europe and the USA. We were able to introduce Resonance Health's services to key international audiences at over 10 conferences and events across 7 countries. We initiated clinician discussions on new indications where FerriScan and HepaFat-Scan have the potential to improve health outcomes; such as the role of our services in both unexplained hyperferritinaemia (elevated iron levels in the blood in the absence of obvious causes of iron-loading) and cancer survivors who have received multiple transfusions. The conferences also facilitated the opportunity to meet many existing customers and new collaborators to progress exciting projects over coming months.

The following are some of the many highlights of the recent "conference season" for Resonance Health:

### International Society of Haematology (ISH) World Congress -Glasgow

A presentation by Professor John Porter of University College London highlighted the insights that can be gained from the combined use of FerriScan and HepaFat-Scan to assist a differential diagnosis in unexplained hyperferritinaemia.

### **Conference Round Up (cont.)**

#### UK Forum on Haemoglobin Disorders - London

This meeting was the official launch for the UK Standards of Care for Thalassaemia. Importantly, the guidelines included recommendations on monitoring and management of iron overload by use of "a validated and standardised MR technique." It stated that "R2 (FerriScan) is preferable to R2\* because the methodology is more robustly standardised and has been licensed for use in routine clinical practice."

This recognition of FerriScan as the preferred technique is expected to result in further uptake by UK clinicians and to assist in the case for reimbursement, both in the UK and elsewhere. To read more about the new standards please <u>click here...</u>

### Sickle Cell In Focus - Bethesda, MD, USA

This conference's move from its traditional home of London to Bethesda, in a new strategy of annual alternation between the UK and USA, yielded more than 500 delegates from all over the world. It proved to be a great opportunity for our US representatives, Sheila Murphy and Pat Corley to expand FerriScan education in the global sickle cell community.

Many key stakeholders were engaged, including Yvonne Carroll, the new President of the International Association of Sickle Cell Nurses and Physician's Assistants (IASCNPA) paving the way for future opportunities to work with this important group.



L to R: Nancy Rene (Axis Foundation), Pat Corley (RH), Sheila Murphy (RH), John James (Chief Executive, Sickle Cell Society. UK), Yvonne Carroll (President IASCNPA)

### European Hematology Association (EHA) Congress - Copenhagen

### Launch of Resonance Health Video

Resonance Health was proud to launch its new corporate video "FerriScan – The Gold Standard in Liver Iron Measurement" at EHA, to an enthusiastic response from delegates. In four minutes, the video, featuring Professor Tim St Pierre and some eye-catching animations, explains the key benefits of FerriScan for patients and clinicians, highlighting its superiority over other methods for measuring liver iron concentration. It also promises to be a valuable resource in helping collaborators such as patient societies and pharmaceutical companies understand and explain the technology. To view the video please <u>click here...</u>



The Resonance Health team discussing FerriScan with EHA delegates

The conference itself provided important opportunities to meet with many existing and potential clients in the haematology field and excellent progress was made in discussions on new study opportunities with Key Opinion Leaders and pharmaceutical companies.

We were also delighted to have a short interview filmed between Professor St Pierre and Dr Josu de la Fuente, a Consultant Paediatric Haematologist and Senior Lecturer at Imperial College London & Director of the Paediatric Blood and Marrow Transplant programme. The interview discussed the clinical benefits of FerriScan – look out for the video on our website over the next few weeks!

Further details of the events in which Resonance Health participated are available <u>here...</u>

#### **Resonance Health News**

# Patient Focus -Unexplained Hyperferritinaemia

Hyperferritinaemia is characterised by elevated levels of serum ferritin in the blood. While this is generally a trigger for genetic testing to assess if a patient has haemochromatosis (a genetic predisposition towards excess iron accumulation), in 90% of Australian cases the results are negative<sup>1</sup>. Further possible causes for the raised iron levels may need to be investigated. These may be:

- Transfusional iron overload where multiple blood transfusions have been given in the course of treatment of anaemia in red cell aplasia (congenital or acquired), haemoglobinopathies, myelodysplastic syndrome, leukaemia or chemotherapy for cancer, severe haemorrage in haemophilia/surgery/trauma
- Iron loading anaemias such as non-transfusion dependant thalassaemia
- Hepatocellular chronic liver disease, such as alcoholic liver disease, Hepatitis B or C, or nonalcoholic steatohepatitis
- Non-HFE Hereditary Haemochromatosis; caused by genetic variants other than those detected in standard genetic tests

The majority of elevated serum ferritin in Australian populations is caused by metabolic syndrome, obesity, diabetes, malignancy, infection and inflammatory conditions or chronic alcohol consumption.

By giving patients a FerriScan together with a HepaFat-Scan (which can be performed in the one MRI scan), clinicians are now able to determine if the cause of the elevated serum ferritin is related to liver iron overload or to conditions associated with a high proportion of liver fat. This may provide valuable information for clinicians to determine the underlying cause and new potential for the utilisation of Resonance Health's technologies.

Ref 1: Elevated serum ferritin; what should GPs know? Australian Family Physician Dec 2012

## International Award for FerriScan Inventor

In May, at a graduation event at the University of Nicosia in Cyprus, Professor Tim St Pierre was awarded the Panos Englezos Prize, in recognition of the contribution FerriScan has made to the lives of thalassaemia patients around the world.



L to R: Prof. Tim St Pierre, Dr Androulla Eleftheriou (TIF Executive Director), Prof Andreas Charalambous (Executive Dean, Medical School of Nicosia)

The prize was established by the Thalassaemia International Federation (TIF), an organisation dedicated to improving access to the highest quality medical care for suffers of thalassaemia and other haemoglobinopathies. Named after Mr Panos Englezos, the long-serving President of TIF, the prize is awarded biannually by the organisation and the University of Nicosia.

This further recognition of the work to which Professor St Pierre has devoted the majority of his working life, in improving monitoring techniques for these conditions and advancing knowledge of their management, is a wonderful accolade to add to the many he and his R&D colleagues have already received.

The prize consists of a silver drop of blood (TIF's logo) and a monetary award of USD \$10,000, which Professor St Pierre has generously donated to provide further access to FerriScan in economically disadvantaged regions. To read more please <u>click here...</u>

# Video for Sickle Cell Patients

Resonance Health's US team was recently invited by Emory Healthcare in Atlanta to submit a short educational video on FerriScan. The objective was to create a simple and straightforward, jargon-free video for sickle cell patients and their families, to help them better understand their treatment options. Pat Corley was able to draw upon her 25 years of nursing experience to explain the technology to patients and the difference that accurate iron measurement makes to their health. The video will be available on the Emory Healthcare website and YouTube.

## **New Clinical Trial**

Resonance Health recently announced that it will provide both FerriScan and Cardiac T2\* services to a pharmaceutical company developing a new treatment for patients with haemoglobinopathies. Resonance Health's Service Centre & Global Program Manager, Emma Stone, said:

"Our quality assured imaging core laboratory services, coupled with standardised, regulatory approved and validated technologies, ideally positions Resonance Health to add value to both pharmaceutical companies and principle investigators seeking robust and comparable data between sites and over time in the complex field of MRI measurement science. We are delighted to be engaged in another study in which we can add value using our technologies to assist in measuring efficacy of interventions."

To read the announcement regarding the study please <u>click</u> <u>here...</u>

For principle investigators seeking more information on Resonance Health's comprehensive core laboratory imaging services, or our existing and new research tools for MRI image analysis in the clinical trial and research setting, please contact <u>emmas@resonancehealth.com</u>

# STOP PRESS – Resonance Health to Feature in Educational Event on Innovation in Medicine

Western Australian-based readers may be interested to visit a display that will feature at the Scitech Discovery Centre, a permanent interactive science museum. On the topic of "Innovation in Medicine", it highlights winners of Innovator of the Year, including Resonance Health. The display, which will be opened for the July school holidays will include a video showcasing HepaFat-Scan and also the new video on "FerriScan – The Gold Standard in Liver Iron Measurement". We are thrilled that Resonance Health's work is being used to inspire the next generation of scientists in Australia.

## Team Member in Focus: Emma Stone - Service Centre & Global Program Manager



Emma's background in genetics and microbiology were the starting point for her career in healthcare and medical devices. A long-standing employee of Resonance Health, Emma initially managed Quality Assurance and Regulatory Affairs. Her current responsibilities are broad and include management of the Service Centre, customer service, contract execution, clinical trial proposals and various collaborative programs. She also oversees the Resonance Health website, social media, and clinical education materials.

Beyond her working life, Emma is also a Mum to energetic six and eight-year-old children and has almost completed her Master of Business Administration at the University of Western Australia. She is definitely a woman who likes to be busy, but is prepared to take time out to explore Western Australia's beautiful bushland or to socialise with family and friends. A self-confessed hippy, Emma is passionate about social justice, animals and the environment.

### **Coming Next Issue...**

- R&D Update
- Cancer Update
- Service and Technical Tips